We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Asset parking

20 June 2017 By Robert Cyran

A wave of consolidation and buyouts among drug outsourcers generated plenty of bids for latest target Parexel. The prospect for cost cuts ought to have given rival companies the upper hand. Yet private-equity shop Pamplona won by offering $4.5 bln, suggesting it paid too much.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)